(Nashua, NH) – Long dominated by nicotine replacement therapy products (NRTs), the historically vapid market for smoking cessation treatments is evolving rapidly into a dynamic sector where a dozen participants are shepherding product candidates through the development and clinical trial process. Rather than employing a methadone-like approach – the NRTs essentially replace the nicotine in smoking products with a less dangerous alternative - these prospective treatments are drugs that actively treat the underlying causes of addiction, and include neuroreceptor modulators, enzyme inhibitors, and therapeutic vaccines. This emerging family of treatments will push worldwide sales of smoking cessation drugs to $1.5 billion by 2010, with much of their growth coming at the expense of NRTs.

The recent FDA approval of Chantix tablets for smoking cessation is considered a watershed for nicotine addiction - and drugs of addiction in general - in that it re-defines smoking cessation as a mainstream healthcare market. The active ingredient in Chantix, varenicline tartrate, is a new molecular entity that received a priority FDA review because of its significant potential benefit to public health

Demand for smoking cessation interventions is increasing in an environment that discourages and denormalizes tobacco use. Smoke-free indoor air policies, tobacco taxation to increase price, and public information campaigns increase interest in stopping smoking. The trend among companies, restaurants, and municipal governments in the U.S. to create smoke-free environments is a key factor driving the growth of the smoking cessation sector.

Smoking Cessation: Next-Generation Targets and Therapies, a recently released report, analyzes existing and emerging smoking cessation products, market participants, and key regulatory and technology factors influencing this market and shaping the growth curve over the next four years. It is available from Applied Data Research by visiting

http://www.applieddata.org/Smoking_Cessation.htm

More information is also available at www.applieddata.org .

About Applied Data

Applied Data Research is a healthcare therapeutics consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Contact:

Greg Stone
Voice: 603-595-6225
Fax: 603-804-0466
www.applieddata.org
Source: Applied Data Research